Skip to main content

RA Capital Healthcare Fund LP's Form 4/A amendment

Amended

Artiva Biotherapeutics, Inc. (ARTV) · filed Jul 23, 2026

Accession no.
0001231919-26-000790
Filed
Jul 23, 2026, 9:21 PM ET
Trade date
Jul 13, 2026
Filing delay
10 days
Rule 10b5-1 plan
Not checked
Original filed
Jul 14, 2026

This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market purchases total $193.8K. It was filed 10 days after the trade.

This amendment restates part of 0001231919-26-000764 (filed Jul 14, 2026). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 0001315082Director, 10% Owner
Ra Capital Management, L.P.CIK 0001346824Director, 10% Owner
Kolchinsky PeterCIK 0001384859Director, 10% Owner
Shah Rajeev M.CIK 0001619841Director, 10% Owner
RA Capital Nexus Fund, L.P.CIK 0001780117Director
RA Capital Nexus Fund III, L.P.CIK 0001883840Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 13, 2026Common StockPPurchaseAcquired+6,522$8.94F2+$58,306.6816,817,543Indirect

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001231919-26-000764 (filed Jul 14, 2026).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001231919-26-000764
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 10, 2026Common StockPPurchaseAcquired+15,102$8.97F1+$135,464.9416,811,021Indirect

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This Form 4/A amends the Form 4 filed on July 14, 2026 to correct the number of shares purchased, which were reported as 6,552, due to a clerical error.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4

Held directly by the Fund.

Read the full filing on SEC EDGAR (opens in a new tab)